Scinai Immunotherapeutics Ltd. Quarterly Operating Income (Loss) in USD from Q1 2022 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Scinai Immunotherapeutics Ltd. annual/quarterly Operating Income (Loss) history and growth rate from Q1 2022 to Q2 2023.
  • Scinai Immunotherapeutics Ltd. Operating Income (Loss) for the quarter ending June 30, 2023 was -$2.6M, a 20.5% increase year-over-year.
  • Scinai Immunotherapeutics Ltd. annual Operating Income (Loss) for 2024 was -$8.64M, a 11% increase from 2023.
  • Scinai Immunotherapeutics Ltd. annual Operating Income (Loss) for 2023 was -$9.71M, a 12.3% increase from 2022.
  • Scinai Immunotherapeutics Ltd. annual Operating Income (Loss) for 2022 was -$11.1M, a 1.83% decline from 2021.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$2.6M +$668K +20.5% Apr 1, 2023 Jun 30, 2023 6-K/A 2023-08-18
Q1 2023 -$3.19M -$571K -21.8% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q2 2022 -$3.26M Apr 1, 2022 Jun 30, 2022 6-K/A 2023-08-18
Q1 2022 -$2.62M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.